<DOC>
	<DOCNO>NCT01022671</DOCNO>
	<brief_summary>A phase II study conduct determine efficacy safety single agent Camtobell inj . ( belotecan ) weekly schedule locally advance metastatic non-small cell lung cancer patient previously treat chemotherapy . The usefulness regimen evaluate response rate , median survival time , progression free survival duration response .</brief_summary>
	<brief_title>Study Camtobell Inj ( Belotecan ) Weekly Schedule Non-small Cell Lung Cancer ( NSCLC ) Patients Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>19 Years old Histologically cytologically confirm locally advanced metastatic NSCLC ( Stage IIIB IV ) ≥ one measureable evaluable lesion , &lt; 25 % bone marrow irradiate prior platinum base chemotherapy ECOG PS ≤ 2 Life expectancy &gt; 3 month Adequate organ function : hematology : ANC ≥ 1.5×109/L , Platelet ≥ 100×109/L , hemoglobin ≥ 9.0g/dL hepatic : total bilirubin ≤ 1.5×ULN , AST/ALT ≤ 2.0×ULN , ALP ≤2.0×ULN renal : serum creatinine ≤ 1.5×ULN Signed write informed consent Active infection Symptomatic brain lesion Any type cancer previous 5 year except appropriately treat basal cell carcinoma skin situ carcinoma cervix Severe concurrent diseases Prior anticancer therapy within 4 week enroll Active pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Belotecan</keyword>
	<keyword>Camtobell inj</keyword>
	<keyword>NSCLC</keyword>
</DOC>